The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS, in relapsed/refractory LBCL.
Roman Fabbricatore
Advertisement
Articles by Roman Fabbricatore
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5